Clinical Trial Update: A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies [Phase 1]

View source ↗

Summary

A Phase 1 study of Imvotamab in active, refractory idiopathic inflammatory myopathies has been terminated (Status: TERMINATED).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Inflammatory Myopathies
• Inflammatory Myopathies

Drugs mentioned

• Imvotamab (imvotamab)

Snippet

Sponsor: IGM Biosciences, Inc. | Conditions: Idiopathic Inflammatory Myopathies, Inflammatory Myopathies | Phase 1 | Status: TERMINATED